Cyrano Therapeutics Presents Promising Results at the 72nd Annual Meeting of the American Rhinologic Society

Cyrano Therapeutics to Present at the 72nd ARS Annual Meeting

Cyrano Therapeutics, Inc., a notable player in the field of regenerative medicine, has announced an exciting opportunity to showcase the findings from its Phase 2 FLAVOR trial at the 72nd Annual Meeting of the American Rhinologic Society (ARS). Set in bustling Los Angeles, from October 15–17, 2026, this event will highlight groundbreaking advancements in the understanding and treatment of olfactory disorders.

Overview of the Presentation

The Phase 2 FLAVOR trial centers around CYR-064, a novel treatment aimed at addressing smell and taste disorders, specifically targeting patients suffering from persistent post-viral hyposmia, a condition that has gained more attention as a consequence of recent global health challenges. Dr. Mas Takashima, the Principal Investigator for the trial, will take center stage to present the results of this study, underlining the significance of the findings.

Study Design and Findings

The FLAVOR trial was structured as a randomized, double-blind, placebo-controlled study. Such a rigorous design ensures the reliability of the outcomes. Throughout the trial, researchers evaluated the safety and efficacy of CYR-064, with notable results emerging that demonstrated a robust safety profile and durability in improving the sense of smell across secondary efficacy endpoints.

Rick Geoffrion, President and CEO of Cyrano Therapeutics, expressed his enthusiasm regarding the selection of the FLAVOR trial for this esteemed venue. He stated, "Presenting these data to leading rhinology and olfactory-disorder specialists is an important opportunity to advance awareness of CYR-064 and its potential to address significant unmet needs for patients living with persistent post-viral smell loss."

This presentation marks a critical advancement in recognizing and treating a condition that has previously seen a considerable gap in available pharmacologic treatment options. The clinical community's growing interest in the problem of persistent olfactory dysfunction cannot be overstated, as it presents substantial challenges for affected patients.

Importance of the ARS Meeting

The American Rhinologic Society’s Annual Meeting serves as a prominent platform for sharing cutting-edge research and clinical advancements in the field of rhinology. By having its findings featured in the